Inter-patient variability and the similarity of healthy and leukemic stem cells (LSCs) have
impeded the characterization of LSCs in acute myeloid leukemia (AML) and their …

Cancer stem cells drive disease progression and relapse in many types of cancer. Despite
this, a thorough characterization of these cells remains elusive and with it the ability to …

Acute myeloid leukemia (AML) is a heterogeneous disease that resides within a complex
microenvironment, complicating efforts to understand how different cell types contribute to …

Background Acute myeloid leukemia (AML) is a heterogeneous and aggressive blood
cancer that results from diverse genetic aberrations in the hematopoietic stem or progenitor …

The treatment landscape of acute myeloid leukemia (AML) is evolving, with promising
therapies entering clinical translation, yet patient responses remain heterogeneous, and …

Acute myeloid leukemia is characterized by the accumulation of clonal myeloid blast cells
unable to differentiate into mature leukocytes. Chemotherapy induces remission in the …

Background Acute myeloid leukemia (AML) is a fatal hematopoietic malignancy and has a
prognosis that varies with its genetic complexity. However, there has been no appropriate …

Background A fundamental challenge for cancer therapy is that each tumor contains a highly
heterogeneous cell population whose structure and mechanistic underpinnings remain …

The plasticity of AML drives poor clinical outcomes and confounds its longitudinal detection.
However, the immediate impact of treatment on the leukemic and non-leukemic cells of the …

In acute myeloid leukemia (AML), novel therapies are needed to target not only the rapidly
dividing AML blasts but also the distinct population of leukemia stem cells (LSCs), which …